

**HER2-POSITIVE TARGETED THERAPY
TOTAL PRESCRIPTIONS
U.S. UNITS BY PRODUCT
Q4 2012 – Q3 2014**

	2012	2013			
	Q4	Q1	Q2	Q3	Q4
IV					
Herceptin®	1,024	1,051	992	1,057	1,034
Kadcyla® ¹		14	145	257	314
Perjeta®	140	180	214	187	217
Non-IV					
Tykerb®	6,059	5,336	4,494	4,000	3,831
Total	7,223	6,581	5,845	5,501	5,396
IV					
Herceptin®	14.2%	16.0%	17.0%	19.2%	19.2%
Kadcyla®		0.2%	2.5%	4.7%	5.8%
Perjeta®	1.9%	2.7%	3.7%	3.4%	4.0%
Non-IV					
Tykerb®	83.9%	81.1%	76.9%	72.7%	71.0%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

Notes & Sources:

¹ Annual Kadcyla® prescriptions totaled 730 in 2013.

Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer with chemotherapy. See, e.g., Exhibit 2317. In contrast:

Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.

Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.

Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2224. (These assertions and sources can be found in the report.)

Includes brand values.

Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'

Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'

Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'

Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'

Values reflect field 'TRx'.

Percentage calculated as percent of quarterly total.

Products identified from Exhibit 2103 and Exhibit 2224.

Data from IMS Health.